Menu
Back to Journals » Lung Cancer: Targets and Therapy » Volume 10
Lung Cancer: Targets and Therapy
ISSN: 1179-2728
- View all (178)
- Volume 15, 2024 (6)
- Volume 14, 2023 (12)
- Volume 13, 2022 (8)
- Volume 12, 2021 (14)
- Volume 11, 2020 (11)
- Volume 10, 2019 (16)
- Volume 9, 2018 (14)
- Volume 8, 2017 (25)
- Volume 7, 2016 (17)
- Volume 6, 2015 (9)
- Volume 5, 2014 (10)
- Volume 4, 2013 (9)
- Volume 3, 2012 (9)
- Volume 2, 2011 (6)
- Volume 1, 2010 (12)
Archive: Volume 10, 2019
Immune Checkpoint Inhibitors for the Treatment of Unresectable Stage III Non–Small Cell Lung Cancer: Emerging Mechanisms and Perspectives
Inoue H, Okamoto I
Lung Cancer: Targets and Therapy 2019, 10:161-170
Published Date: 3 January 2020
Outcomes Following Stereotactic Body Radiotherapy with Intensity-Modulated Therapy versus Three-Dimensional Conformal Radiotherapy in Early Stage Non-Small Cell Lung Cancer
Mix M, Tanny S, Nsouli T, Alden R, Chaudhari R, Kincaid R, Rosenbaum PF, Bogart JA, Aridgides P
Lung Cancer: Targets and Therapy 2019, 10:151-159
Published Date: 20 December 2019
Approaches to Tumor Classification in Pulmonary Sarcomatoid Carcinoma
Baldovini C, Rossi G, Ciarrocchi A
Lung Cancer: Targets and Therapy 2019, 10:131-149
Published Date: 5 December 2019
Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies
Gadgeel S, Shaw AT, Barlesi F, Crino L, Yang JCH, Dingemans AM, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Smoljanovic V, Ou SHI
Lung Cancer: Targets and Therapy 2019, 10:125-130
Published Date: 13 November 2019
Landscape on CT screening for lung cancer in Asia
Triphuridet N, Henschke C
Lung Cancer: Targets and Therapy 2019, 10:107-124
Published Date: 30 September 2019
A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors
Nagasaka M, Abdallah N, Crosby M, Thummala N, Patel D, Wozniak AJ, Gadgeel S, Abrams J, Sukari A
Lung Cancer: Targets and Therapy 2019, 10:95-105
Published Date: 12 September 2019
Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date
Facchinetti F, Friboulet L
Lung Cancer: Targets and Therapy 2019, 10:87-94
Published Date: 9 September 2019
TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations
Ouseph MM, Taber A, Khurshid H, Madison R, Aswad BI, Resnick MB, Yakirevich E, Ali SM, Patel NR
Lung Cancer: Targets and Therapy 2019, 10:81-86
Published Date: 15 August 2019
Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkers
Stratmann JA, Sebastian M
Lung Cancer: Targets and Therapy 2019, 10:67-80
Published Date: 1 July 2019
Impact of smoking on frequency and spectrum of K-RAS and EGFR mutations in treatment naive Indonesian lung cancer patients
Masykura N, Zaini J, Syahruddin E, Andarini SL, Hudoyo A, Yasril R, Ridwanuloh A, Hidajat H, Nurwidya F, Utomo A
Lung Cancer: Targets and Therapy 2019, 10:57-66
Published Date: 17 June 2019
Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer
Weinberg F, Gadgeel S
Lung Cancer: Targets and Therapy 2019, 10:47-56
Published Date: 4 June 2019
Pain management in patients with malignant mesothelioma: challenges and solutions
Saunders J, Ashton M, Hall C, Laird B, MacLeod N
Lung Cancer: Targets and Therapy 2019, 10:37-46
Published Date: 2 April 2019
Targeting RET-rearranged non-small-cell lung cancer: future prospects
Bronte G, Ulivi P, Verlicchi A, Cravero P, Delmonte A, Crinò L
Lung Cancer: Targets and Therapy 2019, 10:27-36
Published Date: 20 March 2019
Differential response to a combination of full-dose osimertinib and crizotinib in a patient with EGFR-mutant non-small cell lung cancer and emergent MET amplification
Zhu VW, Schrock AB, Ali SM, Ou SI
Lung Cancer: Targets and Therapy 2019, 10:21-26
Published Date: 12 March 2019
Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
Barrows SM, Wright K, Copley-Merriman C, Kaye JA, Chioda M, Wiltshire R, Torgersen KM, Masters ET
Lung Cancer: Targets and Therapy 2019, 10:11-20
Published Date: 8 February 2019
Outcome of uncommon EGFR mutation positive newly diagnosed advanced non-small cell lung cancer patients: a single center retrospective analysis
Kate S, Chougule A, Joshi A, Noronha V, Patil V, Dusane R, Solanki L, Tiwrekar P, Trivedi V, Prabhash K
Lung Cancer: Targets and Therapy 2019, 10:1-10
Published Date: 29 January 2019